Clinical Trial Update: Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating switching virologically suppressed HIV-1 patients to a fixed-dose combination of bictegravir/emtricitabine/tenofovir alafenamide (B/F/T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Bictegravir/Emtricitabine/Tenofovir Alafenamide (Bictegravir/emtricitabine/tenofovir alafenamide)

Snippet

Sponsor: Gilead Sciences | Conditions: HIV-1 Infection | Phase 3 | Status: COMPLETED | Results posted: 2020-08-27